Tourmaline Bio, Inc. (TRML)

Tourmaline Bio Market Cap

Tourmaline Bio has a market cap or net worth of $396.24 million as of April 19, 2024. Its market cap has increased by 401.57% in one year.

• Market Cap: 396.24M
• Enterprise Value: 193.48M
• 1-Year Change: 401.57%
• Ranking: #3117
• Category: Small-Cap
• Stock Price: $15.45

Market Cap Chart

Since May 7, 2021, Tourmaline Bio's market cap has decreased from $670.10M to $396.24M, a decrease of -40.87%. That is a compound annual growth rate of -16.30%.

Market Cap History

Date	Market Cap	% Change
Apr 19, 2024	396.20M	-1.34%
Apr 18, 2024	401.60M	-6.12%
Apr 17, 2024	427.80M	-6.59%
Apr 16, 2024	458.00M	-5.95%
Apr 15, 2024	487.00M	-5.77%
Apr 12, 2024	516.80M	0.25%
Apr 11, 2024	515.50M	0.96%
Apr 10, 2024	510.60M	-13.02%
Apr 9, 2024	587.00M	-0.88%
Apr 8, 2024	592.20M	2.12%
Apr 5, 2024	579.90M	2.97%
Apr 4, 2024	563.20M	0.27%
Apr 3, 2024	561.70M	0.47%
Apr 2, 2024	559.10M	-7.39%
Apr 1, 2024	603.70M	2.79%
Mar 28, 2024	587.30M	-
Mar 27, 2024	587.30M	-3.86%
Mar 26, 2024	610.90M	0.05%
Mar 25, 2024	610.60M	-3.49%
Mar 22, 2024	632.70M	-13.77%
Mar 21, 2024	733.70M	-35.95%
Mar 20, 2024	1.15B	10.76%
Mar 19, 2024	1.03B	27.11%
Mar 18, 2024	813.70M	-7.36%
Mar 15, 2024	878.30M	3.52%

View and export this data all the way back to 2021. Sign Up Today.

Related Stocks

Company	Market Cap
Avid Bioservices	404.10M
Pulse Biosciences	397.07M
Lexeo Therapeutics	397.02M
Heron Therapeutics	396.87M
NeuroPace	396.26M
Replimune Group	395.95M
Revance Therapeutics	393.94M
Mersana Therapeutics	391.89M